Roche Reports the US FDA Acceptance of sBLA and Granted Priority Review for Tecentriq (atezolizumab) as 1L Monotherapy for Advanced Non-Small Cell Lung Cancer

 Roche Reports the US FDA Acceptance of sBLA and Granted Priority Review for Tecentriq (atezolizumab) as 1L Monotherapy for Advanced Non-Small Cell Lung Cancer

Roche Reports the US FDA Acceptance of sBLA and Granted Priority Review for Tecentriq (atezolizumab) as 1L Monotherapy for Advanced Non-Small Cell Lung Cancer

Shots:

  • The sBLA submission is based on P-III IMpower110 study assessing Tecentriq as monothx. vs CT in 572 PD-L1-selected (TC3/IC3-WT), CT-naïve patients with advanced sq. or non-sq. NSCLC without ALK or EGFR mutations
  • The P-III Impower110 study results: improvement in OS by 7.1mos. (20.2 vs 13.1mos.), the safety profile is consistent with its known safety profile with no new signals observed
  • Tecentriq is a mAb targeting PD-L1, blocking its interaction with both PD-1 and B7.1 receptor with its anticipated FDA’s decision on approval for this indication by Jun 19, 2020

Click here ­to­ read full press release/ article | Ref: Roche | Image: Bloomberg

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post